The SHARP registry demonstrates comparable efficacy of biologic therapies in severe asthma patients across never-smokers, ex-smokers, and current smokers.
Improvements in symptom control, asthma-related quality of life, exacerbation frequency, and oral corticosteroid use were consistent regardless of smoking pack-year history.
Despite evidence, a notable proportion of European clinicians remain reluctant to prescribe biologics to current smokers, reflecting gaps between guidelines and practice.
The findings emphasize the necessity of targeted randomized controlled trials involving smokers to refine asthma treatment guidelines inclusively.
